TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02504359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given BEAM chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given BEAM chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given BEAM chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given BEAM chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT03387436

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-Intervention
Description: The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study-Intervention
Description: The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten.
Study: NCT04622332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIR1-365
Description: Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Route of administration: oral
Study: NCT03434171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic excercise
Description: practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy products
Description: diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy products
Description: diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
Study: NCT03764891

Intervention type: PROCEDURE
Intervention: Uphold
Description: Uphold system in treating women with cystocele

Intervention type: PROCEDURE
Intervention: Perigee
Description: Perigee system in treating women with cystocele
Study: NCT03051282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
Study: NCT03100669

Intervention type: PROCEDURE
Intervention: Pectus surgery
Description: Patients undergoing surgical repair of pectus excavatum or carinatum
Study: NCT00812799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: 19.000 BU daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: placebo control
Study: NCT02140333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg vs. 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 100mg vs. 150mg
Study: NCT04042168

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In Check Dial test
Description: In Check Dial test will test the ability to actuate the inhaler.
Study: NCT01466530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
Study: NCT01963429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: \* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: \* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)
Study: NCT00419146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (EPA)
Description: Capsules, 2 g per day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (EPA)
Description: Capsules, 2 g per day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamins E + C
Description: RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamins E + C
Description: RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etyl EPA (placebo)
Description: Paraffin oil. Capsules, each 0.5 g.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamins E+C (placebo)
Description: Tablets containing dicalciumphosphate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamins E+C (placebo)
Description: Tablets containing dicalciumphosphate
Study: NCT02024568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description
Study: NCT03923751

Intervention type: OTHER
Intervention: Invitation to regional anesthesia survey
Description: An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
Study: NCT02218957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pouch RYGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RYGB
Study: NCT01751399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study: NCT04553705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Indian Costus
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Quinine pills
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Anise seed capsule
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Standard protocol care of COVID-19 infection
Study: NCT02032550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference Based Decision Aid
Description: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
Study: NCT04807855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cMLP device
Description: There is only one medical device we are testing, so only one intervention.
Study: NCT00003865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Study: NCT05855057

Intervention type: PROCEDURE
Intervention: Flank suspended supine position percutaneous nephrolithotomy
Description: The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.

Intervention type: PROCEDURE
Intervention: Supine percutaneous nephrolithotomy group
Description: The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.

Intervention type: PROCEDURE
Intervention: Prone percutaneous nephrolithotomy group
Description: Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
Study: NCT00073528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500 mg orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (which matched with lapatinib tablet)
Study: NCT02467283

Intervention type: GENETIC
Intervention: Genom-based whole-genome transcriptomic
Description: Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.

Intervention type: GENETIC
Intervention: Genom-based whole-genome transcriptomic
Description: Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
Study: NCT01881945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive physiological signal recording on healthy volunteer
Study: NCT06011564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder function on Android computer tablet
Description: Computer tablet with reminder function
Study: NCT02282566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
Study: NCT03975101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
Study: NCT02039804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Intra-bursal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Intra-bursal injection
Study: NCT02746133

Intervention type: OTHER
Intervention: Observational study: Supplemented protein-restricted diet
Description: Observational study: Supplemented protein-restricted diet
Study: NCT00003702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intramuscularly
Study: NCT03007979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional research biopsy
Description: Patients may consent to paired tumor biopsies at baseline and time of progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell blood draw
Description: -Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy (optional)
Description: -Baseline and progression
Study: NCT00733954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray
Description: Apply twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate ointment
Description: Apply twice daily
Study: NCT01406236

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transradial PCI
Description: Transradial PCI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transfemoral PCI
Description: Transfemoral PCI
Study: NCT02522507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment
Description: Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
Study: NCT03286686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: point targets
Description: In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: point targets
Description: In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tactile stimulation
Description: In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Description: Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Description: Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Description: Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
Study: NCT00482703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, Oral, 100 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: tablets, Oral, 50 mg, twice daily
Study: NCT00225979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Study: NCT01056172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and Ribavirin
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a and Ribavirin
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks
Study: NCT04643080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: 6 oz. of a commercially available yogurt were provided daily for 12 weeks
Study: NCT00602095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 0.025mg tablet vaginally every 4 hour until progress

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone
Description: 2mg vaginal gel every 6 hours until progress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Catheter (balloon catheter)
Description: Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
Study: NCT00843518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY451395
Description: 3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily for 12 weeks